Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Generic drug approvals boost pharma firms' global ambitions

By Liu Zhihua | China Daily | Updated: 2019-03-07 11:42
Share
Share - WeChat
Many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. [Photo/VCG]

Chinese pharmaceutical companies are strengthening their presence on the world stage with an increasing number of generic drug approvals from the United States, thanks to rising research and development capabilities and official support for innovation, industry insiders said.

According to statistics from the Healthcare Executive Institute, a leading healthcare industry think tank based in Beijing, as of Dec 24, 2018, Chinese pharmaceutical companies had received 77 generic drug approvals - known as abbreviated new drug applications or ANDAs - from the US Food and Drug Administration.

The number was 38 in 2017 and 22 in 2016. Before 2016, Chinese pharmaceutical companies had fewer than 15 ANDAs approved on average each year.

A recent example is a generic drug made by Qingdao Baheal Pharmaceutical Ltd, a holding subsidiary of Baheal Pharmaceutical Group headquartered in Beijing and Qingdao, Shandong province.

Its generic drug Nida, which is an extended-release tablet containing metformin, a medicine widely used to manage type-2 diabetes, was approved by the USFDA on Dec 27, 2018.

The company announced earlier that the first batch of the drug was about to be delivered to the US market.

The think tank said one reason behind the rise in approvals is that many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. Another reason is that once a generic drug receives US approval, it is automatically seen as having passed China's generic consistency evaluation requirements.

In 2016, the Chinese central authorities issued an opinion on "conducting consistency evaluations of the quality and efficacy of generic drugs", signaling a push for an industrywide overhaul of generic drug quality. Failure to pass the evaluation before the required deadline leads to revocation of the drug title's registration license or ineligibility for government tendering. Besides, if three titles of a generic drug have passed the evaluation, others will not be allowed for government tendering.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, added that the Chinese authorities' recent policies are very supportive of innovation and high-quality generic drug research and development, providing solid incentives for Chinese pharmaceutical companies to file more ANDAs.

"If a Chinese generic drug gains US approval, it is often fast tracked by Chinese authorities when it applies for domestic approval, giving it an advantage in the fiercely competitive domestic generic drug market," he said.

Shen Yaping, vice-president with Jiangsu Hengrui Medicine Co Ltd, a top Chinese pharmaceutical company listed in Shanghai, said the company now files new generic drug applications to domestic and US authorities for this reason.

"Going global and innovation are the two most important development strategies for our company, and now we feel encouraged, because a lot of government policies are inspiring to companies like us that want to expand overseas business," Shen said.

The overseas markets, especially the US, are large and alluring, yet in the past, Chinese pharmaceutical companies lacked the ability to expand overseas, he said, adding that as a number of first-tier Chinese pharmaceutical companies have succeeded in developing overseas business, others are trying to keep up with them.

His company and its subsidiary Shanghai Hengrui Pharmaceutical Co Ltd have received 16 ANDA approvals, according to its website.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 97国产在线播放| 少妇无码av无码专区线| 无码国产精品一区二区免费模式| 宅男66lu国产在线观看| 国产精品永久免费视频| 欧美亚洲人成网站在线观看 | 韩国爸爸的朋友10整有限中字| 色8久久人人97超碰香蕉987| 青娱乐欧美视频| 青娱乐手机在线| va天堂va亚洲va影视中文字幕| 91精品综合久久久久久五月天| 日本免费a视频| 色偷偷亚洲第一综合网| 清早可以吃西瓜吗| 暖暖免费高清日本一区二区三区| 成全动漫视频在线观看免费播放| 天堂在线最新资源| 国产日韩av在线播放| 再深点灬舒服灬太大女女| 亚洲国产精品久久久久秋霞小| 久久久精品日本一区二区三区| Av鲁丝一区鲁丝二区鲁丝三区| 黄页网址在线免费观看| 99精品国产成人一区二区| 四虎国产精品高清在线观看| 美国一级毛片免费| 欧美午夜电影在线观看| 尾野真知子日韩专区在线| 国产日韩欧美综合一区| 伊人久久大香线蕉电影院| 亚洲va欧美va天堂v国产综合| 一区二区三区免费精品视频| 欧美丝袜一区二区三区| 男人天堂网在线视频| 日韩aⅴ人妻无码一区二区| 在车子颠簸中进了老师的身体| 国产一级生活片| 国产亚洲欧美在线| 国产精品欧美一区二区三区| 国产亚洲欧美日韩精品一区二区|